Cyclic urea derivatives as potent NK1 selective antagonists

Bioorganic and Medicinal Chemistry Letters

Volumn 15, Issue 17, 2005, Pages 3896-3899

  Shue, Ho Jane ^a   Chen, Xiao ^a   Shih, Neng Yang ^a   Blythin, David J ^a   Paliwal, Sunil ^a   Lin, Ling ^a   Gu, Danlin ^a   Schwerdt, John H ^a   Shah, Sapna ^a   Reichard, Gregory A ^a,b   Piwinski, John J ^a   Duffy, Ruth A ^a   Lachowicz, Jean E ^a   Coffin, Vicki L ^a   Liu, Fei ^a   Nomeir, Amin A ^a   Morgan, Cynthia A ^a   Varty, Geoffrey B ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SUBSTANCE P ANTAGONIST; UREA DERIVATIVE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG BRAIN LEVEL; DRUG PENETRATION; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; NONHUMAN;

ANIMALS; BIOLOGICAL AVAILABILITY; DOSE-RESPONSE RELATIONSHIP, DRUG; GERBILLINAE; HETEROCYCLIC COMPOUNDS; MOTOR ACTIVITY; PROTEIN BINDING; RATS; RECEPTORS, NEUROKININ-1; STRUCTURE-ACTIVITY RELATIONSHIP; UREA;

EID: 23244466620     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2005.05.111     Document Type: Article

References (20)

1. S. Guard, and S.P. Watson Neurochem. Int. 18 1991 149
2. M. Otsuka, and K. Yoshioka Physiol. Rev. 73 1993 229
3. J.A. Lowe III Med. Res. Rev. 16 1996 527
4. T. Hökfelt, B. Pernow, and J. Wahren J. Intern. Med. 249 2001 27
5. S. McLean Med. Res. Rev. 16 1996 297
6. K. Sekizawa, Y.X. Jia, T. Ebihara, Y. Hirose, Y. Hirayama, and H. Sasaki Pulm. Pharmacol. 9 1996 323
7. E.M. Seward, and C.J. Swain Expert Opin. Ther. Patents 9 1999 571
8. C.A. Maggi, A. Giachetti, R.D. Dey, and S.I. Said Physiol. Rev. 75 1995 277
9. N. Yonehara, and M. Yoshimura Pain 92 2001 259
10. C. Gardner, and M. Perren Neuropharmacology 37 1998 1643
11. J.J. Hale, S.G. Mills, M. MacCoss, P.E. Finke, M.A. Cascieri, S. Sadowski, E. Ber, G.G. Chicchi, M. Kurtz, J. Metzger, G. Eiermann, N.N. Tsou, F.D. Tattershall, N.M.J. Rupniak, A.R. Williams, W. Rycroft, R. Hargreaves, and D.E. MacIntyre J. Med. Chem. 41 1998 4607
12. A. Saria Eur. J. Pharmacol. 375 1999 51
13. R.A. Duffy Exp. Opin. Emerg. Drugs 9 2004 9
14. C.J. Swain, M.A. Cascieri, A. Owens, W. Saari, S. Sadowski, C. Strader, M. Teall, M.B. Van Niel, and B.J. Williams Bioorg. Med. Chem. Lett. 4 1994 2161
15. For more experimental details see: Shih, N.-Y.; Shue, H.-J.; Reichard, G. A.; Paliwal, S.; Blythin, D. J.; Piwinski, J. J.; Xiao, D.; Chen, X. PCT Int. Appl. WO 0144200, 2001.
16. G.A. Reichard, C. Stengone, S. Paliwal, I. Mergelsberg, S. Majmundar, C. Wang, R. Tiberi, A.T. McPhail, J.J. Piwinski, and N.-Y. Shih Org. Lett. 23 2003 4249
17. i values were obtained using the Cheng and Prusoff equation.
18. 1 antagonists were administered orally in 0.4% methylcellulose in distilled water at a dose of 1 mg/kg (unless otherwise stated) at various pretreatment times prior to injection of GR73632. Data are expressed as a percent decrease (% inhibition) in the amount of time spent foot tapping compared to vehicle-treated controls.
19. M.A. Cascieri, A.M. Macleod, D. Underwood, L.-L. Shiao, E. Ber, S. Sadowski, H. Yu, K.J. Merchant, C.J. Swain, C.D. Strader, and T.M. Fong J. Biol. Chem. 269 1994 6587
20. N.M.J. Rupniak, and A.R. Williams Eur. J. Pharmacol. 265 1994 179